Mental Health Clinics in Clinton, NY Accepting Medicare
11 Mental Health Clinics found. Showing 1 - 11
 Jennie Mazza Jones Lcsw Pllc Social Worker - Clinical Medicare: Not Enrolled in Medicare Practice Location: 2 Williams St Ste 2, Clinton, NY 13323 Phone: 315-737-3094 |
Jennifer L Smith Md Pllc Psychiatry & Neurology - Neurology Medicare: Not Enrolled in Medicare Practice Location: 1 Kirkland Ave Apt 302, Clinton, NY 13323 Phone: 315-381-3402 Fax: 315-732-2315 |
Joshua D. Burgess Lcsw Social Worker - Clinical Medicare: Not Enrolled in Medicare Practice Location: 63 Norton Ave, Clinton, NY 13323 Phone: 315-424-3415 |
Jean M Baker Social Worker - Clinical Medicare: Not Enrolled in Medicare Practice Location: 3 Fountain St Ste 201, Clinton, NY 13323 Phone: 315-292-4834 Fax: 315-266-1366 |
Clinton Therapy And Testing Center Clinic - Mental Health Medicare: Medicare Enrolled Practice Location: 7325 Ny State Route 5, Clinton, NY 13323 Phone: 315-859-1973 Fax: 315-859-1979 |
Integrated Behavioral Wellness, Llc Social Worker - Clinical Medicare: Not Enrolled in Medicare Practice Location: 2 Fountain St, Ste 110, Clinton, NY 13323 Phone: 315-381-3101 |
Flourish Counseling & Consulting Lcsw Pllc Social Worker - Clinical Medicare: Not Enrolled in Medicare Practice Location: 63 Norton Ave, Clinton, NY 13323 Phone: 315-795-4321 Fax: 315-533-4377 |
Countryside Mental Health Counseling Pllc Clinic - Mental Health Medicare: Not Enrolled in Medicare Practice Location: 7254 State Route 5, Clinton, NY 13323 Phone: 315-557-8893 |
J Michel Associate Social Worker Medicare: Not Enrolled in Medicare Practice Location: 36 Kellogg St, Clinton, NY 13323 Phone: 315-859-1470 Fax: 315-859-1480 |
Center For Addiction Recovery Community/Behavioral Health Agency Medicare: Not Enrolled in Medicare Practice Location: 7930 Limberlost Rd, Clinton, NY 13323 Phone: 315-853-7111 Fax: 315-853-7762 |
Clinton Therapy & Testing Center Psychologist - Clinical Medicare: Medicare Enrolled Practice Location: 7325 State Route 5, Clinton, NY 13323 Phone: 315-859-1973 Fax: 315-859-1979 |
News Archive
Oral delivery of PYY hormone can help obese people lose weight
Most people understand that serious weight loss requires changing attitudes toward what they eat and how often they exercise. But, what if the process could be aided by simply chewing a stick of gum after meals? That's the question a team of scientists, led by Syracuse University chemist Robert Doyle, is trying to answer. In a groundbreaking new study, Doyle's team demonstrated, for the first time, that a critical hormone that helps people feel "full" after eating can be delivered into the bloodstream orally.
Blood test may help identify risk of bladder cancer recurrence after surgery
A blood test that can detect tiny amounts of circulating cancer DNA may be able to identify risk of cancer recurrence and guide precision treatment in bladder cancer following surgery, according to a clinical study led byProfessor Tom Powles from Queen Mary University of London andBarts Health NHS Trust.
AACE publishes consensus statement for continuous glucose monitoring
The American Association of Clinical Endocrinologists (AACE) today published a consensus statement for continuous glucose monitoring (CGM) online, and the statement will be published in the next issue of the association's official medical journal Endocrine Practice.
Scientists identify kidney failure susceptibility gene
Scientists at Johns Hopkins schools of Public Health and Medicine have, for the first time, identified variants in the gene MYH9 that are associated with increased risk for non-diabetic end stage renal disease (ESRD,) which is the near-loss of kidney function leading to either dialysis of transplant. MYH9, located on the 22 chromosome, is the first gene identified for common forms of kidney disease.
AVEO Pharmaceuticals presents tivozanib's Phase 2 trial data at ASCO meeting
AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced data from a subgroup analysis of a Phase 2 randomized discontinuation trial showing that the median progression-free survival (PFS) achieved by patients with advanced clear cell renal cell carcinoma (RCC) who had undergone a prior nephrectomy was 14.8 months.
› Verified 8 days ago